Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 2Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × utomilumab × Lymphoid × Clear all
NCT03636503 2025-02-06

Rituximab + Immunotherapy in Follicular Lymphoma

Dana-Farber Cancer Institute

Phase 1 Terminated
24 enrolled 25 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT02951156 2020-12-17

Javelin DLBCL

Pfizer

Phase 3 Terminated
29 enrolled 24 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡